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Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in
Otherwise Healthy Cigarette Smokers
Sowmya Venkatasubramanian, MD; Radzi Mohd Noh, MD; Shruti Daga, MD, PhD; Jeremy P. Langrish, MD, PhD; Nikhil V. Joshi, MD, PhD;
Nicholas L. Mills, MD, PhD; Ethan Hoffmann; Eric W. Jacobson, MD; George P. Vlasuk, PhD; Brian R. Waterhouse, MS; Ninian N. Lang, MD,
PhD; David E. Newby, PhD, MD
Background-—We examined the effect of the oral SIRT1 activator SRT2104 on cardiovascular function in otherwise healthy
cigarette smokers.
Methods and Results-—Twenty-four otherwise healthy cigarette smokers participated in a randomized double-blind, placebo-
controlled crossover trial and received 28 days of oral SRT2104 (2.0 g/day) or matched placebo. Plasma SRT2104 concentrations,
serum lipid proﬁle, plasma ﬁbrinolytic factors, and markers of platelet and monocyte activation were measured at baseline and at
the end of each treatment period together with an assessment of forearm blood ﬂow during intra-arterial bradykinin, acetylcholine,
and sodium nitroprusside infusions. Three hours postdose, mean plasma SRT2104 concentration was 1328748 ng/mL after 28
days of active treatment. Compared with placebo, serum lipid proﬁle improved during SRT2104 administration, with reductions in
serum total cholesterol (11.620 versus 621 mg/dL), low-density lipoprotein cholesterol (1017 versus 321 mg/dL), and
triglyceride (39.877 versus 13.357 mg/dL) concentrations (P<0.05 for all). All vasodilators produced a dose-dependent
increase in blood ﬂow (P<0.0001) that was similar during each treatment period (P>0.05 for all). No signiﬁcant differences in
ﬁbrinolytic or blood ﬂow parameters were observed between placebo and SRT2014.
Conclusions-—SRT2104 appears to be safe and well tolerated and associated with an improved lipid proﬁle without demonstrable
differences in vascular or platelet function in otherwise healthy cigarette smokers.
Clinical Trial Registration-—http://www.clinicaltrials.gov. Unique identiﬁer: NCT01031108. ( J Am Heart Assoc. 2013;2:
e000042 doi: 10.1161/JAHA.113.000042)
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O riginally identiﬁed in yeast, sirtuins represent a class ofhighly conserved nicotinamide adenine dinucleotide
(NAD)–dependent histone deacetylases that have 7 identiﬁed
members in mammalian species.1,2 They have been impli-
cated in the beneﬁcial effects of calorie restriction on
longevity in several species and are promising drug targets
for a variety of diseases of aging.3 Sirtuin (silent mating type
information regulation 2 homolog) 1 (SIRT1) is the best-known
member of this class of proteins and is expressed broadly in
multiple tissues and highly expressed in the vascular endo-
thelium.4 SIRT1 inhibition is associated with vascular dys-
function and arterial thrombosis5 as well as alterations in
ﬁbrinolysis.6 Conversely, SIRT1 activation is associated with
improved endothelial function,7 enhanced lipid metabolism,8
and inhibition of atherogenesis.9
Smoking tobacco remains one of the most important and
consistent modiﬁable risk factors for coronary heart disease
and is associated with an up to 7-fold increased risk of
nonfatal myocardial infarction.10 It is associated with both
accelerated atherosclerosis11 and a propensity for acute
coronary thrombosis.12,13 This is mediated through a variety
of mechanisms including alterations in vascular, endothelial,
ﬁbrinolytic, and platelet function.14–17 The precise cellular
mechanism for these effects is as yet unknown, but cigarette
smoke is associated with oxidative stress, endothelial nitric
oxide synthase acetylation, and increased endothelial cell
senescence that has been attributed to reduced SIRT1 levels.4
To date, there have been few clinical studies to assess the
effect of SIRT1 activation in vivo in humans. Therefore, the
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aim of the present study was to examine the in vivo effects of
a novel oral SIRT1 activator, SRT2104, on the lipid proﬁle and
vascular, endothelial, and platelet function in otherwise
healthy cigarette smokers. We hypothesized that SIRT1
activation could improve the cardiovascular risk proﬁle and
reverse or improve the vascular and endothelial dysfunction
associated with cigarette smoking.
Methods
The studywas approved by the Research Ethics Committee, was
given Clinical Trial Authorization by the Medicines and Health-
care products Regulatory Authority (MHRA), and carried out at
theMHRA Phase 1 accredited Wellcome Trust Clinical Research
Facility at the Royal Inﬁrmary of Edinburgh, United Kingdom,
between June 2010 and September 2011. Written informed
consent was obtained from each volunteer, and the study was
carried out in accordance with the Declaration of Helsinki.
Study Participants
Twenty-four otherwise healthy male and female volunteers
aged between 18 and 70 years who smoked ≥10 cigarettes
daily for at least 1 year were eligible for the study. Exclusion
criteria included the presence of signiﬁcant comorbidities,
chronic illness, renal or liver impairment, history of gastroin-
testinal diseases or surgeries inﬂuencing drug absorption,
history of alcoholism, history of neoplastic disease within the
last 5 years, a positive urinary test for recreational drugs,
pregnancy, and participation in other clinical trials or blood
donation within the last 3 months. Eligibility of participants
including absence of relevant medical history was conﬁrmed
through a standardized form completed by the registered
general practitioners after informed consent. Tests for
pregnancy (serum human chorionic gonadotrophin [HCG]
concentrations at screening and urinary HCG concentrations
at study visits) were conducted on all female participants of
child-bearing potential.
Study Design
This was a prospective double-blind, randomized, placebo-
controlled crossover study (1:1 SRT2104:placebo). Subjects
were randomized to receive 2.0 g daily of oral SRT2104 or
matched placebo (Sirtris Pharmaceuticals Inc) for a 28-day
period, followed by crossover to the alternate study arm for
another 28 days, giving a total dosing duration of 56 days. An
end-of-study visit was conducted on day 70, with a phone call
follow-up on day 86. Assessment of drug safety, tolerability,
and efﬁcacy on vascular function was carried out at baseline
and during and at the end of each treatment period (Figure 1).
Vascular Studies
Vascular studies were undertaken before and at the end of
each 28-day trial period. All studies were performed with the
patient lying supine in a quiet temperature-controlled (22°C to
25°C) room. Participants were fasted and asked to refrain
from smoking for 10 hours before the study and to avoid
caffeine and alcohol for 24 hours before the study. Venous
Figure 1. Study design: schematic representation of study design. PK indicates pharmacokinetic; SCR, screening.
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cannulas (17G) were inserted into large subcutaneous veins in
the antecubital fossae of both arms at the start of the study to
facilitate periodic venous sampling. Supine heart rate and
blood pressure were monitored at intervals throughout the
study using a semiautomated noninvasive oscillometric
sphygmomanometer (Omron 705 IT).
Forearm Venous Occlusion Plethysmography
Forearm blood ﬂow was measured in the infused and
noninfused forearms using forearm venous occlusion plethys-
mography as described previously.17 Subjects underwent
brachial artery cannulation in the nondominant forearm with
a 27 standard-wire-gauge steel needle. After a 20-minute
baseline infusion with 0.9% saline, incremental intra-arterial
doses of bradykinin (American Peptide Co) at 100, 300, and
1000 pmol/min (an endothelium-dependent vasodilator that
evokes tissue plasminogen activator [t-PA] release); acetyl-
choline (Chem. Pharm Fabrik GmBH) at 5, 10, and 20 lg/min
(an endothelium-dependent vasodilator that does not evoke
t-PA release); and sodium nitroprusside (Hospira Inc) at 2, 4,
and 8 lg/min (an endothelium-independent vasodilator that
does not evoke t-PA release) were infused for 6 minutes at
each dose, with a 30-minute 0.9% saline washout infusion
between drugs. The order of drugs was randomized between
subjects but kept constant for each subject across the 3 visits.
Blood Sampling
Paired venous blood samples were obtained from each
forearm before and during the infusion of intra-arterial
bradykinin. Samples were collected into acidiﬁed buffered
citrate (Stabilyte; Trinity Biotech Plc) and citrate (BD Vacu-
tainer; BD UK Ltd) for determination of t-PA and plasminogen-
activator inhibitor type 1 (PAI-1) concentrations, respectively.
Samples were placed on ice before centrifuging at 2000g for
30 minutes at 4°C. Platelet-free plasma was decanted and
stored at 80°C before further analysis. Venous blood
samples were collected into EDTA at the beginning and end
of the vascular study to determine hematocrit.
Plasma t-PA antigen and activity (t-PA Combi Actibind t-PA
ELISA kit; Technoclone, Vienna, Austria) and PAI-1 antigen and
activity (Elitest PAI-1 Antigen and Zymutest PAI-1 Activity;
Hyphen Biomed) concentrations were determined by enzyme-
linked immunosorbent assays (ELISAs).
Platelet and Monocyte Activation
Flow-cytometric measurements of platelet–monocyte
aggregation (PMA) and platelet surface expression of
P-selectin and monocyte CD11b expression (Mac-1/CD11b)
were performed at baseline and at the end of each treatment
period as described previously.16,18,19 Brieﬂy, peripheral
venous blood was drawn from a large antecubital vein and
anticoagulated with the direct thrombin inhibitor D-phenylal-
anine-L-arginine chloromethyl ketone (75 lmol/L PPACK;
Cambridge Biosciences) and immunolabeled within 5 minutes
of phlebotomy for subsequent ﬂow cytometric analysis.
Directly conjugated monoclonal antibodies were obtained
from DakoCytomation and Serotec. Samples were stained
with the following conjugated monoclonal antibodies:
phycoerythrin (PE)–conjugated CD14, PE-conjugated CD62p,
PE-conjugated CD11b, ﬂuorescein isothiocyanate (FITC)–
conjugated 42a, and FITC-conjugated CD14 and appropriate
control isotypes. Once stained, samples were incubated for
20 minutes at room temperature before being ﬁxed with
FACS-Lyse (Becton-Dickinson). All samples were analyzed
using a FACS Calibur ﬂow cytometer using CellQuestPro
software (Becton-Dickinson).
Venous blood was collected in citrate at baseline and after
each dosing period to assess plasma-soluble CD40 ligand
(sCD40L) concentrations. Blood was centrifuged at 1500g for
15 minutes at 4°C, and plasma was decanted and stored at
80°C for further analysis by ELISA (Bender Medsystems).
Safety and Pharmacokinetic Analyses
Venous blood samples were collected biweekly to measure
hematological and biochemical analytes including full blood
count, coagulation proﬁle, liver and renal function, creatine
phosphokinase, lactate dehydrogenase, lipid proﬁle°C and
free fatty acids. Analyses were conducted by the regional
clinical hematology and biochemistry reference laboratories
using an automated hematology analyzer (XE2100, Sysmex
Corporation and ACL TOP, Instrumentation Laboratory), an
automated chemistry analyzer using colorimetric, kinetic and
enzymatic ultraviolet and color assays (AU2700/AU640
analyzers, Beckman & Coulter), ion-selective electrodes
(sodium, potassium, and chloride assays) and 2-point and
multiple-point rate assays (Ortho Clinical Vitros 250 analyzer).
Venous blood samples were taken into prelabeled heparin-
ized sodium tubes for pharmacokinetic assessment of plasma
SRT2104 concentrations (Simbec Laboratories Limited). Serial
blood samples were collected on days 1, 28, and 56
immediately before (0 minutes) and 15, 30, 60, 120, 180,
240, 480, 720 and 1440 minutes following study medication.
Plasma was separated by centrifugation of whole blood at
1500g at 4°C for 15 minutes, and decanted and stored at
80°C until analyzed.
Methodology of SRT2104 Analysis
Plasma concentrations of SRT2104 were measured using
liquid chromatography with tandem mass spectrometry
DOI: 10.1161/JAHA.113.000042 Journal of the American Heart Association 3
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detection in positive ion mode. High-pressure liquid chroma-
tography was performed using Betasil silica–100 columns
using a Phenomenex C18 guard column.22
Data Analysis and Statistics
Plethysmographic datawere analyzed asdescribed previously.21
Estimated net release of t-PA and PAI-1 antigen and activity was
deﬁned as the product of forearm plasma ﬂow (based on blood
ﬂow and hematocrit) and the difference in plasma antigen (or
activity) concentrations between the 2 forearms. On the basis of
previous power calculations,20 a sample size of 20 gives 80%
power to detect a change in net t-PA antigen release of 27.0 ng/
100 mL of tissue per minute, assuming a standard deviation of
40.0 and a 2-sided P<0.05 (paired t test). To account for a 20%
dropout rate, we recruited 24 subjects.
Fibrinolysis and forearm blood ﬂow data were analyzed
using a linear mixed-model repeated-measures analysis of
covariance. Treatment differences were investigated in a
model adjusting for period, treatment by period, vasodilator
dose, treatment by vasodilator dose, and vasodilator dose by
period using SAS for UNIX (version 9.1.3 or higher; SAS
Institute). Values for these parameters are expressed as model
adjusted (least square means) and 95% conﬁdence intervals.
Between-day reproducibility of forearm venous occlusion
plethysmography data was assessed using the Bland–Altman
method, and coefﬁcient of reproducibility was determined for
95% conﬁdence intervals using the Student t distribution. All
other values are expressed as meanSD.
Results
Study Participants
Volunteers had a mean age of 3813 years (median,
37 years) and relatively equal sex distribution (58% male)
and were normotensive without any signiﬁcant coexisting
medical conditions. Volunteers had a body mass index of
254 kg/m2 and a mean cigarette consumption of 176
cigarettes per day over 2114 years. The mean urinary
cotinine concentration at screening was 1352950 ng/mL.
All 24 volunteers completed all study visits. Before drug
administration, 1 subject was withdrawn from the study
because of problems with venous access and was replaced.
Pharmacokinetics, Tolerability, and Safety
Three hours postdose, mean plasma SRT2104 concentration
was 1328748 ng/mL after 28 days of active treatment
(Figure 2). The median plasma SRT2104 concentration after
28 days of treatment was 366 ng/mL (IQR, 940 ng/mL). The
median time at which the maximum plasma concentration
was observed (Tmax) on day 28 of dosing was 3.05 hours,
which coincided well with study measurements performed on
those days (2 to 4 hours postdose). The geometric mean area
under the curve (AUC0-s) was 6412 h  ng/mL. Consistent
with previous observations,22 there was substantial intersub-
ject variability in exposure during this study.
All subjects tolerated study medication well. Commonly
reported side effects included headache (25%) and rhinitis,
nasopharyngitis, and respiratory tract symptoms (17%)
(Table 1). The reported adverse events were mild in intensity
and resolved without any intervention or sequelae. There were
no meaningful differences in the number of events between
active treatment and placebo. There was only 1 reported
serious adverse event in the study (SRT2104 arm): a traumatic
facial bone fracture that was considered unrelated to SRT2104.
Blood pressure and heart rate remained unchanged
throughout the study. There were no effects on cardiac rhythm
or the 12-lead electrocardiogram, and speciﬁcally there were
no effects on the corrected or uncorrected QT intervals. There
were no clinically signiﬁcant adverse effects involving any of
the clinical hematological or biochemical analytes.
Lipid Proﬁle
Treatment with SRT2104 had a favorable effect on the lipid
proﬁle. A statistically signiﬁcant period effect was observed in
the analysis of total and low-density lipoprotein (LDL)
cholesterol concentrations. Baseline values were higher in
subjects receiving placebo in the ﬁrst period. Regardless of
treatment arm, the level of change from baseline was greater
in period 2 for total and LDL cholesterol and less in period 2
for triglycerides. Adjusted summaries combined over period
are presented in Table 2. There was a reduction in total and
LDL cholesterol as well as triglyceride concentrations. There
Figure 2. Pharmacokinetics: mean plasma concentration–time
curve following oral dosing of SRT2104 on day 1 (closed circles)
and day 28 (open circles). Data presented as meanSD.
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Table 1. List of Adverse and Serious Adverse Events
System Symptom (AE/SAE)
Number of Events
Placebo (n=24) SRT2104 (n=24)
Any event — 18 18
Nervous system disorders Headache 4 6
Paresthesia 0 2
Hypoesthesia 1 2
Carpal tunnel syndrome 0 1
Presyncope 1 1
Burning sensation 0 1
Sciatica 0 1
Respiratory, thoracic, and mediastinal disorders Oropharyngeal pain 1 2
Rhinorrhea 0 1
Gastrointestinal disorders Flatulence 1 0
Mouth ulceration 0 1
Abdominal pain upper 1 0
Hemorrhoids 1 0
Reproductive system and breast disorders Dysmenorrhea 3 1
Musculoskeletal and connective tissue disorders Back pain 2 0
Musculoskeletal chest pain 1 0
Musculoskeletal pain 1 0
Myalgia 0 1
Investigational Blood bilirubin increased 1 1
Creatinine phosphokinase increased 1 0
LDH increased 1 0
AST increased 1 0
General disorders and administration site conditions Inﬂuenza-like illness 1 0
Fatigue 1 0
Catheter site pain 0 1
Catheter site rash 1 0
Catheter site–related reaction 1 0
Catheter site swelling 1 0
Edema peripheral 0 1
Pyrexia 0 1
Swelling 0 1
Infections and infestations Nasopharyngitis 0 1
Rhinitis 2 2
Upper respiratory tract infection 1 0
Oral herpes 0 1
Respiratory tract infection 0 1
Injury, poisoning, and procedural complications Contusion 1 0
Excoriation 1 1
Arthropod bite 1 0
Facial bones fracture* 0 1
Laceration 1 0
Continued
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was no effect on high-density lipoprotein concentrations, and
the 7% fall in total cholesterol was attributable to the 11% fall
in LDL cholesterol concentrations.
Vasomotor Function
Noninfused forearm blood ﬂow remained unchanged through-
out all assessment periods, as were the predose measure-
ments of blood ﬂow in the infused arm between visits
(P>0.05). There was a dose-dependent increase in the infused
forearm blood ﬂow with all 3 agonists (acetylcholine,
bradykinin, and sodium nitroprusside) in the presence of
either SRT2104 or placebo (P<0.0001 for all 3 agonists;
Figure 3). There were no signiﬁcant differences in response
to either endothelium-dependent or -independent vasodilators
in the presence of SRT2104 compared with placebo (brady-
kinin, P=0.1169; acetylcholine, P=0.1683; sodium nitroprus-
side, P=0.9039: placebo versus SRT2104). There were no
differences in forearm vasodilatation between the baseline
and placebo visits of the study for all 3 agonists (P=0.5649,
P=0.4009, and P=0.2908 for bradykinin, acetylcholine, and
sodium nitroprusside, respectively), conﬁrming the good
reproducibility of the measurements (Table 3).
Endogenous Fibrinolysis and Monocyte and
Platelet Activation
There was a dose-dependent increase in bradykinin-evoked
net t-PA antigen and activity release (P<0.0001 for both) in
the infused arm that was unaffected by SRT2104 (P=0.3691
and P=0.1377, placebo versus SRT2104, for net t-PA antigen
and activity, respectively; Table 4). Plasma plasminogen
activator inhibitor-1 (PAI-1) activity decreased with time
during all study visits (P<0.05), consistent with its circadian
variation and t-PA release. Plasma PAI-1 antigen and activity
concentrations were similar in both treatment arms
(P=0.8877 and P=0.6635, placebo versus SRT2104, for
plasma PAI antigen and activity, respectively).
SRT2104 had no effect on markers of in vivo platelet or
monocyte activation (Figure 4).
Discussion
In this randomized, double-blind, placebo-controlled crossover
trial of otherwise healthy cigarette smokers, we have
demonstrated that oral SRT2104 is safe and well tolerated
at a dose of 2.0 g daily. Importantly, we have shown that
Table 1. Continued
System Symptom (AE/SAE)
Number of Events
Placebo (n=24) SRT2104 (n=24)
Skin and subcutaneous tissue Rash 1 0
Metabolism and nutrition disorders Decreased appetite 0 1
Vascular disorders Phlebitis 0 1
Eye disorders Eye pain 1 0
Vision blurred 0 1
Ear and labyrinthine disorders Motion sickness 0 1
Surgical and medical procedures Vasectomy 1 0
*Serious Adverse Event.
AE indicates adverse event; SAE, serious adverse event; LDH, lactate dehydrogenase; AST, aspartate aminotransferase.
Table 2. Effect of SRT2104 on Serum Lipid Concentrations
Placebo (n=22) SRT2104 (n=20)
Total cholesterol (meanSD), mg/dL
Baseline 17454 17650
Day 28/56 18051 16447
Change from baseline 621 1220*
HDL cholesterol, mg/dL
Baseline 4611 4710
Day 28/56 5013 5116
Change from baseline 37 47
LDL cholesterol, mg/dL
Baseline 9941 9937
Day 28/56 10237 8834
Change from baseline 321 1017*
Triglycerides, mg/dL
Baseline 133110 140114
Day 28/56 146149 10067
Change from baseline 1357 4077*
*P<0.05.
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein.
DOI: 10.1161/JAHA.113.000042 Journal of the American Heart Association 6
SIRT1 Activators in Endothelial Dysfunction Venkatasubramanian et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
treatment with SRT2104 was associated with an 11% mean
reduction in serum LDL cholesterol concentrations, but
without demonstrable differences in vasomotor function,
endothelial function, or platelet activation assessments
compared with placebo. The favorable effects on lipid proﬁle
suggest that SIRT1 activation may have a beneﬁcial role in
Figure 3. Effect of bradykinin (100, 300, 1000 pmol/min), acetylcholine (5, 10, 20 lg/min), and sodium nitroprusside (2, 4, 8 lg/min) on
absolute forearm blood ﬂow. Blue, placebo; red, SRT2104; closed circle, infused forearm blood ﬂow; open circle, noninfused forearm blood ﬂow.
Data presented as mean95% conﬁdence interval.
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patients at risk of developing or with established cardiovas-
cular disease.
Elevated serum cholesterol is an established risk factor
for atherosclerosis and coronary heart disease. In general,
coronary heart disease risk is reduced by 2% to 3% for each
1% decrease in total cholesterol concentrations.23 We
observed a 7% mean reduction in serum total cholesterol
and an 11% mean reduction in LDL cholesterol concentra-
tions without affecting serum high-density lipoprotein cho-
lesterol concentrations. The mechanism of this lipid-lowering
effect is not entirely clear but is consistent with observa-
tions associated with SIRT1 activation in animals. Resvera-
trol (3,5,4′-trihydroxy-trans-stilbene) is a naturally occurring
polyphenolic compound that is believed to confer health
beneﬁts through SIRT1 activation.24 Resveratrol has been
found to lower plasma triglycerides and cholesterol
accumulation in guinea pigs25 and to suppress atherogenic
lesion formation in apolipoprotein E–deﬁcient mice.26
Indeed, SRT2104 also lowers triglyceride levels in preclinical
murine models of dyslipidemia, diabetes, and obesity as well
as improving insulin sensitivity and metabolic function in
these animals.27 One mechanism whereby SIRT1 activators
such as SRT2104 could improve lipid proﬁles may involve a
positive regulatory effect on liver X receptor proteins (LXRs),
nuclear receptors involved in cholesterol and lipid homeo-
stasis. Nuclear receptor LXR is a substrate for SIRT1. Li
and colleagues have shown that SIRT1 deacetylates and
positively regulates this receptor, potentially altering cho-
lesterol transport and metabolism.28 Although the exact
mechanism of the improved lipid proﬁles seen with SIRT1
activation remains to be determined, our ﬁndings would
suggest that SIRT1 activation could provide a therapeutic
adjunct to current lipid-lowering strategies, leading to
improvements in cardiovascular disease pathophysiology
and thus clinical outcomes.
There are currently no published data directly examining
the effects of SIRT1 activation on vasomotor function or
endogenous ﬁbrinolysis in vivo in humans. Despite the several
beneﬁcial effects of SIRT1 activation on endothelial function
observed in preclinical in vitro studies,6,7,29–31 we were unable
to demonstrate improvements in vascular, endothelial, or
platelet function in these otherwise healthy smokers. Why
was this?
Did we use appropriate and sufﬁciently sensitive
techniques? Forearm venous occlusion plethysmography is a
well-established technique that has been used extensively
over the years to study human vascular physiology and has
been considered a gold standard in the assessment of
vascular function in health and disease.32 Using endothelium-
dependent (bradykinin and acetylcholine) and -independent
(sodium nitroprusside) vasodilators, we observed a dose-
dependent increase in forearm arterial vasodilatation with all
3 agonists. Our results are comparable with those reported in
previously published studies17,33–35 in otherwise healthy
cigarette smokers including impaired t-PA release.15,36,37
Moreover, our data had low variance and were highly
reproducible when we compared the baseline responses with
those obtained during placebo administration. Similarly, ﬂow
cytometric analysis is considered a sensitive gold standard for
measurement of in vivo platelet activation. We have previously
shown that in patients with peripheral arterial disease,
measurements of platelet–monocyte aggregates are
reproducible and consistently reﬂect other markers of platelet
and monocyte activation.38 In the present study, we again
report comparable levels of platelet–monocyte aggrega-
tion19,39 that were reproducible between visits.
There is a body of published data that conﬁrms a strong
association between cigarette smoking, endothelial dysfunc-
tion, and impaired endogenous ﬁbrinolysis.4,14,17,21,40 We
were interested to see if this vascular and endothelial
dysfunction could be improved or reversed by SIRT1 activa-
tion. There could be numerous explanations why we failed to
achieve improvement with SRT2104 in these parameters in
the current study. One possibility is that the SRT2104
exposure achieved in this study did not lead to adequate or
consistent SIRT1 activation, which would be required to
reverse the vascular and endothelial dysfunction in these
smokers. Unfortunately, there is no current biomarker for
SIRT1 activation or the ability to measure SIRT1 activation
directly in humans. Therefore, we do not have a good
understanding of the pharmacokinetic-pharmacodynamic
relationship between SRT2104 drug exposure and SIRT1
activation. Although we were able to demonstrate improved
lipid proﬁles, it is unclear whether the same exposure levels
Table 3. Between-Day Repeatability of Forearm Blood Flow
Drug Dose
Mean of Differences
in Forearm Blood Flow
(mL/100 mL per minute)
Coefﬁcient of
Repeatability
(mL/100 mL
per minute)
Bradykinin,
pmol/min
100 0.3 5
300 0.5 6
1000 0.2 7
Acetylcholine,
lg/min
5 0.1 8
10 0.5 8
20 0.3 7
Sodium
nitroprusside,
lg/min
2 0.2 5
4 0.3 6
8 0.7 6
Between-day reproducibility (baseline vs placebo visit) in absolute forearm blood ﬂow for
bradykinin (100, 300, 1000 pmol/min), acetylcholine (5, 10, 20 lg/min), and sodium
nitroprusside (2, 4, 8 lg/min).
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would also lead to improved vascular and endothelial function.
There are at least 70 known substrates for SIRT1. SRT2104
may differentially deacetylate certain substrates in preference
to others, depending on the precise interaction between
SRT2104 and the substrates as well as the level and activity
of the substrates in a particular disease state. It is also
possible that certain abnormalities may be reversed more
readily than others through SIRT1 activation. Although a 28-
day exposure may be adequate for observing improvement in
lipid proﬁles, longer treatment may be required to reverse
some of the vascular and endothelial abnormalities. The small
sample size of our study may also be a potential limitation.
SRT2104 is the ﬁrst selective SIRT1 activator to be studied in
human clinical trials. As the biology of SIRT1 becomes more
established and additional data are gathered from small
exploratory trials such as this one, the optimal approach for
developing SIRT1 activators and identifying disease states
with the greatest therapeutic potential will become better
deﬁned.
In conclusion, we have demonstrated that the oral SIRT1
activator SRT2104 is safe and well tolerated in otherwise
healthy cigarette smokers and provides positive effects on
lipid proﬁles, but were unable to demonstrate beneﬁcial
effects on vascular, endothelial, or platelet function compared
with placebo.
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